Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16961227 | 0.83 | APOBEC3G (0.44) | TAAR1CYP2A6NR4A2GAAPTGDR2 | |
| SCHEMBL12373156 | 0.83 | PNMT (0.39) | PNMTTAAR1AKR1B1GAAIDO1 | |
| SCHEMBL29471364 | 0.83 | TAAR1 (0.39) | PNMTTAAR1CYP1A2AKR1B1GAA | |
| SCHEMBL23694192 | 0.83 | TAAR1 (0.39) | PNMTTAAR1CYP1A2AKR1B1GAA | |
| SCHEMBL31655644 | 0.83 | PNMT (0.39) | PNMTTAAR1AKR1B1GAAIDO1 | |
| SCHEMBL31396696 | 0.82 | DPP4 (0.48) | PNMTTAAR1CYP1A2CYP2A6NR4A2 | |
| SCHEMBL79943 | 0.79 | TAAR1 (0.37) | PNMTTAAR1CYP1A2AKR1B1GAA | |
| SCHEMBL3069271 | 0.79 | PNMT (0.43) | PNMTTAAR1CYP1A2CYP2A6AKR1B1 | |
| SCHEMBL17552713 | 0.79 | PNMT (0.43) | PNMTTAAR1CYP1A2CYP2A6AKR1B1 | |
| SCHEMBL559225 | 0.79 | PNMT (0.67) | PNMTTAAR1CYP1A2AKR1B1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122536-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-6861561-B2 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | claimed |
| US-20050043294-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-6803388-B2 | TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASES; STEREOSELECTIVE; CHEMICAL INTERMEDIATES | PFIZER, INC. | 2004-10-12 | — | — | US | claimed |
| US-6787570-B2 | ADMINISTERING AN AROMATIC OR HETEROAROMATIC SUBSTITUTED TERTIARYAMINE COMPOUND TO TREAT ATHEROSCLEROSIS, DYSLIPIDEMIA, AND OTHER CORONARY ARTERY DISEASES | PFIZER, INC. | 2004-09-07 | — | — | US | claimed |
| US-6765023-B2 | SUCH AS 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR TREATING CARDIOVASCULAR DISORDERS AND DYSLIPIDEMIA | PFIZER, INC. | 2004-07-20 | — | — | US | claimed |
| US-6723752-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-6723753-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-6710089-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS; ANTICHOLESTEROL AGENTS | PHARMACIA CORPORATION | 2004-03-23 | — | — | US | claimed |
| US-20040044048-A1 | (R)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2004-03-04 | — | — | US | claimed |
| US-6451830-B1 | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | claimed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | claimed |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-08-29 | — | — | US | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043294-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | CETP, DBI, MTTP | PNMT 1567/4885TAAR1 2041/4885CYP1A2 2385/4885 |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | PNMT 368/4885TAAR1 1689/4885CYP1A2 2762/4885 |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, DBI | PNMT 510/4885TAAR1 1766/4885CYP1A2 3905/4885 |
| US-20040044048-A1 | (R)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | PNMT 1216/4885TAAR1 1343/4885CYP1A2 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.